Radioimmunotherapy is a therapeutic strategy that combines targeted antibodies with radionuclide payloads to deliver radiation selectively to tumors, thereby improving RT-induced immunotherapeutic outcomes. In the cited studies, it was applied against lung cancer and evaluated in a pancreatic cancer model using trop 2-directed antibodies labeled with 177Lu, 225Ac, and 212Pb. A 2026 Advanced Materials study (PMID:41914367) reported a HAEPRC platform that synergized with gene editing for cocktail-sensitized radioimmunotherapy of lung metastases, highlighting combination approaches to enhance efficacy. Biomarker-guided optimization is emerging as a major theme, including predictive biomarkers for precision use and toxicity prediction markers for safety management. Overall, the literature emphasizes radionuclide selection, target specificity, and patient stratification as key determinants of therapeutic success.
Lung cancer
- A 2026 International Journal of Cancer review framed radioimmunotherapy as a bench-to-bedside strategy for lung cancer and highlighted biomarker discovery as central to clinical translation. (PMID:41603296)
- Predictive biomarkers were identified as a key research question for advancing precise radioimmunotherapy in lung cancer. (PMID:41603296)
- Toxicity-prediction markers were discussed as important for safety management in radioimmunotherapy. (PMID:41603296)
- A 2026 Advanced Materials study showed that a HAEPRC platform combined with gene editing could sensitize radioimmunotherapy for lung metastases. (PMID:41914367)
Targeted radionuclide delivery
- trop 2-directed radioimmunotherapy was tested with three radionuclides: 177Lu, 225Ac, and 212Pb. (PMID:41591978)
- The same study evaluated these radionuclide payloads in a pancreatic cancer model, supporting target-specific delivery beyond lung disease. (PMID:41591978)
- The relation set indicates that 177Lu, 225Ac, and 212Pb function as radionuclide payloads delivered by the antibody-based platform. (PMID:41591978)
- This work underscores how radionuclide choice can be tuned within radioimmunotherapy to balance therapeutic effect and safety. (PMID:41591978)
Immunotherapy enhancement
- The Key Facts describe radioimmunotherapy as a therapeutic strategy that improved RT-induced immunotherapeutic outcomes. (PMID:41914367)
- Pd-mediated bioorthogonal catalysis activated immune-adjuvant production to enhance anti-tumor immunity, suggesting a mechanism for combination benefit. (PMID:41914367)
- The HAEPRC platform exemplifies a combined radiotherapy-immunotherapy approach designed to boost immune response. (PMID:41914367)